يعرض 1 - 10 نتائج من 77 نتيجة بحث عن '"Corinne Veyret"', وقت الاستعلام: 1.70s تنقيح النتائج
  1. 1
    Abstract P1-18-19: Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)

    المؤلفون: Hélène Francois-Martin, Audrey Lardy-Cleaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Corinne Veyret, Antony Goncalves, Michael Chevrot, Paul H Cottu

    المصدر: Cancer Research. 82:P1-18

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cddd262d0a4d23c88442e78afbeb0b6dTest
    https://doi.org/10.1158/1538-7445.sabcs21-p1-18-19Test


    أضف إلى المفضلة
  2. 2
    Abstract P4-05-02: Impact of hormone receptor status on clinicopathological characteristics and outcomes among HER2-positive metastatic breast cancer patients in the ESME database

    المؤلفون: Luc Cabel, Matthieu Carton, Veronique Dieras, Thierry Petit, Severine Guiu, Corinne Veyret, Anthony Goncalves, Lionel Uwer, Paule Augereau, Jean-Marc Ferrero, Christelle Levy, Florence Dalenc, Isabelle Desmoulins, Marie Ange Mouret-Reynier, Marc Debled, Thomas Bachelot, Jean-Christophe Eymard, Barbara Pistilli, Jean Sebastien Frenel, Michael Chevrot, Audrey Mailliez, Marcela Carausu

    المصدر: Cancer Research. 82:P4-05

    مصطلحات موضوعية: Cancer Research, Oncology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ad191291a7ee680c0135a5ef7d3440baTest
    https://doi.org/10.1158/1538-7445.sabcs21-p4-05-02Test


    أضف إلى المفضلة
  3. 3
    Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer

    المؤلفون: Laureline Lefebvre, Olivier Rigal, Marie Gilles-Baray, Marianne Leheurteur, Cristian Moldovan, Isabelle Tennevet, Dragos Georgescu, Olivier Rastelli, Cristina Alexandru, Michael Bubenheim, Corinne Veyret, Florian Clatot, Amélie Poullain, J. Lequesne, Jean-Christophe Thery, Cécile Guillemet, Frédéric Di Fiore, Camille Petrau, Julien Gouérant, Laetitia Savary, Sophie Gouérant, Maxime Fontanilles

    المساهمون: Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Unité de recherche clinique [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Unité d'Oncologie Digestive

    المصدر: European Journal of Cancer
    European Journal of Cancer, Elsevier, 2020, 126, pp.116-124. ⟨10.1016/j.ejca.2019.11.022⟩

    مصطلحات موضوعية: 0301 basic medicine, Adult, Cancer Research, medicine.medical_specialty, Catheterization, Central Venous, Adjuvant chemotherapy, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Breast Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Patient satisfaction, Quality of life, Risk Factors, Antineoplastic Combined Chemotherapy Protocols, Catheterization, Peripheral, medicine, Central Venous Catheters, Humans, In patient, Adverse effect, Early Detection of Cancer, Aged, Chemotherapy, business.industry, Hazard ratio, Middle Aged, medicine.disease, 3. Good health, Surgery, 030104 developmental biology, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Catheter-Related Infections, Quality of Life, Female, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9113d471a132452980edfc26e157dbe2Test
    https://hal.archives-ouvertes.fr/hal-03489892Test


    أضف إلى المفضلة
  4. 4
    Cognitive Changes After Adjuvant Treatment in Older Adults with Early‐Stage Breast Cancer

    المؤلفون: Bénédicte Giffard, Nadine Longato, Johan Lefel, Francis Eustache, Alexandra Leconte, Jean-Emmanuel Kurtz, Florence Joly, Bénédicte Clarisse, Olivier Rigal, Corinne Veyret, Christelle Levy, Hélène Castel, Philippe Barthélémy, Natacha Heutte, Laure Tron, D. Allouache, Marie Lange, Chantal Rieux, Sabine Noal

    المساهمون: Bodescot, Myriam, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Plateforme Cancer et Cognition, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Ligue Nationale Contre le Cancer (LNCC)-Cancéropole Nord-Ouest, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychologie et imagerie de la mémoire humaine (NIMH), Normandie Université (NU)-Normandie Université (NU)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), This work was supported by a national grant (Programme Hospitalier de Recherche Clinique, grant APN 2008 no 06–08) and Sanofi. The Northwest Data Center (CTD-CNO) is acknowledged for managing the data. It is supported by grants from the French National League Against Cancer (LNC) and the French National Cancer Institute (INCa)., Centre de recherche clinique [CHU Caen] (CRC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER, Centre d’études des transformations des activités physiques et sportives (CETAPS), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Comité Sein [Caen], UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Service d'Oncologie médicale [CHU Caen], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Unité de Recherche clinique [Caen], Service d'Oncologie médicale [Rouen], ChemBioPharm, Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Neuropsychologie cognitive et neuroanatomie fonctionnelles de la mémoire humaine, École nationale supérieure des sciences de l'information et des bibliothèques (ENSSIB), Université de Lyon, Normandie Université (NU)-Normandie Université (NU)-Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Normandie Université (NU)-École pratique des hautes études (EPHE)-Institut National de la Santé et de la Recherche Médicale (INSERM), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Cancéropole Nord-Ouest-Ligue Nationale Contre le Cancer (LNCC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)

    المصدر: Oncologist
    Oncologist, 2019, 24 (1), pp.62-68. ⟨10.1634/theoncologist.2017-0570⟩
    Oncologist, AlphaMed Press, 2019, 24 (1), pp.62-68. ⟨10.1634/theoncologist.2017-0570⟩

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Aging, Cognition disorders, [SDV]Life Sciences [q-bio], [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease, Systemic therapy, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Adjuvant therapy, Humans, Chemotherapy, 030212 general & internal medicine, Cognitive skill, Cognitive decline, ComputingMilieux_MISCELLANEOUS, Aged, business.industry, Cancer, Cognition, medicine.disease, 3. Good health, Geriatric Oncology, Oncology, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Cognitive changes, Female, Breast neoplasms, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5e2ce32b189903eab57c2bc6680f79Test
    https://doi.org/10.1634/theoncologist.2017-0570Test


    أضف إلى المفضلة
  5. 5
    Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer:Long-Term Follow-up of the BiG 1-98 Trial

    المؤلفون: Maj-Britt Jensen, Carlo Tondini, Erik Jakobsen, Beat Thürlimann, Corinne Veyret, Meredith M. Regan, Richard D. Gelber, Anita Giobbie-Hurder, Marco Colleoni, Khalil Zaman, Lorenzo Gianni, Edda Simoncini, Elena Kralidis, Laurence Gladieff, Thomas Ruhstaller, Hervé Bonnefoi, Bent Ejlertsen, Martine Piccart-Gebhart, Simon Spazzapan, Patrick Neven, István Láng, Jacek Jassem, Christoph Rochlitz, Vernon Harvey, Lucia Del Mastro, Angelo Di Leo, Alan S. Coates, Evandro de Azambuja, Aron Goldhirsch

    المصدر: BIG 1-98 Collaborative Group and the International Breast Cancer Study Group 2019, ' Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer : Long-Term Follow-up of the BiG 1-98 Trial ', Journal of Clinical Oncology, vol. 37, no. 2, pp. 105-114 . https://doi.org/10.1200/JCO.18.00440Test
    Ruhstaller, T, Giobbie-Hurder, A, Colleoni, M, Jensen, M-B, Ejlertsen, B, de Azambuja, E, Neven, P, Láng, I, Jakobsen, E H, Gladieff, L, Bonnefoi, H, Harvey, V J, Spazzapan, S, Tondini, C, Del Mastro, L, Veyret, C, Simoncini, E, Gianni, L, Rochlitz, C, Kralidis, E, Zaman, K, Jassem, J, Piccart-Gebhart, M, Di Leo, A, Gelber, R D, Coates, A S, Goldhirsch, A, Thürlimann, B, Regan, M M & members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group 2019, ' Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer : Long-Term Follow-Up of the BIG 1-98 Trial ', Journal of Clinical Oncology, vol. 37, no. 2, pp. 105-114 . https://doi.org/10.1200/JCO.18.00440Test

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Breast Neoplasms, Disease-Free Survival, Drug Administration Schedule, law.invention, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Double-Blind Method, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Aged, business.industry, Letrozole, ORIGINAL REPORTS, Middle Aged, medicine.disease, Postmenopause, Clinical trial, Natural history, Tamoxifen, 030104 developmental biology, Receptors, Estrogen, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Observational study, Receptors, Progesterone, business, medicine.drug

    وصف الملف: application/pdf

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ead057538ca8996e76354c7935d3fc6Test
    https://curis.ku.dk/portal/da/publications/adjuvant-letrozole-and-tamoxifen-alone-or-sequentially-for-postmenopausal-women-with-hormone-receptorpositive-breast-cancerTest(77aa4539-c2c8-49b0-a38f-a32c983678f0).html


    أضف إلى المفضلة
  6. 6
    Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients

    المؤلفون: M. Gilles-Baray, Sophie Gouérant, Cristian Moldovan, D. Georgescu, I. Tennevet Bouilly, M. Fontanilles, Camille Petrau, Cristina Alexandru, Marianne Leheurteur, Olivier Rastelli, J. Lequesne, Michael Bubenheim, J. Gouérant, Olivier Rigal, Laureline Lefebvre, Corinne Veyret, Cécile Guillemet, Florian Clatot, Jean-Christophe Thery, F. Di Fiore

    المصدر: Annals of Oncology. 30:v739

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, Hematology, Neutropenia, medicine.disease, Thrombosis, Surgery, law.invention, Clinical trial, Port (medical), Oncology, Randomized controlled trial, law, medicine, Clinical endpoint, Complication, Adverse effect, business

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4a0416eb4a832ee2e2b6199e23ccce7cTest
    https://doi.org/10.1093/annonc/mdz265.062Test


    أضف إلى المفضلة
  7. 7
    Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

    المؤلفون: Jean Michel Picquenot, Cristina Alexandru, Julien Delacour, Marianne Leheurteur, Jean Christophe Thery, Isabelle Tennevet, Frédéric Di Fiore, Cécile Guillemet, Thierry Frebourg, Elodie Bohers, Claire Dolfus, Antoine Dujon, Cristian Moldovan, David Sefrioui, Nasrin Sarafan-Vasseur, Olivier Rigal, Corinne Veyret, Florian Clatot, Marie Cornic, Anne Perdrix

    المصدر: International Journal of Cancer. 137:2513-2519

    مصطلحات موضوعية: Oncology, CA15-3, Cancer Research, medicine.medical_specialty, medicine.drug_class, Context (language use), Biology, medicine.disease_cause, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Aromatase, 030304 developmental biology, 0303 health sciences, Mutation, Aromatase inhibitor, medicine.disease, Metastatic breast cancer, Primary tumor, 3. Good health, body regions, 030220 oncology & carcinogenesis, biology.protein

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::091a175e5bec20c196616b188a19c227Test
    https://doi.org/10.1002/ijc.29612Test


    أضف إلى المفضلة
  8. 8
    Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC)

    المؤلفون: Mikkel Z. Oestergaard, Gunter von Minckwitz, István Láng, Andrea Fontana, Cristian Villanueva, Sabine de Ducla, Eduard Vrdoljak, Joseph Gligorov, Gilles Romieu, Norbert Marschner, Eva Ciruelos, Javier Cortes, Ulrich Freudensprung, Christoph C. Zielinski, Corinne Veyret, Fabio Puglisi

    المصدر: Cancer Research. 75:P3-06

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, education.field_of_study, Randomization, Bevacizumab, business.industry, Hazard ratio, Population, Cancer, medicine.disease, Gastroenterology, Metastatic breast cancer, Breast cancer, Oncology, Internal medicine, medicine, Clinical endpoint, Nuclear medicine, business, education, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dfbe8227b74e78d4cadce7af9da74b1fTest
    https://doi.org/10.1158/1538-7445.sabcs14-p3-06-08Test


    أضف إلى المفضلة
  9. 9
    Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

    المؤلفون: Eduard Vrdoljak, Christoph C. Zielinski, Cristian Villanueva, Joseph Gligorov, Fabio Puglisi, Ulrich Freudensprung, Sabine de Ducla, Gilles Romieu, Javier Cortes, Stefanie Srock, Michelino De Laurentiis, Gunter von Minckwitz, Corinne Veyret, István Láng, Eva Ciruelos, Norbert Marschner

    المساهمون: von Minckwitz, Gunter, Puglisi, Fabio, Cortes, Javier, Vrdoljak, Eduard, Marschner, Norbert, Zielinski, Christoph, Villanueva, Cristian, Romieu, Gille, Lang, István, Ciruelos, Eva, DE LAURENTIIS, Michelino, Veyret, Corinne, de Ducla, Sabine, Freudensprung, Ulrich, Srock, Stefanie, Gligorov, Joseph

    المصدر: The Lancet Oncology. 15:1269-1278

    مصطلحات موضوعية: Oncology, Time Factors, genetic structures, medicine.medical_treatment, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, genetics, skin and connective tissue diseases, Humanized, education.field_of_study, Medicine (all), drug therapy/genetics/mortality/pathology, Remission Induction, Middle Aged, Metastatic breast cancer, Bevacizumab, Treatment Outcome, Local, Retreatment, metastatic breast cancer, Drug, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Combination therapy, Population, Breast Neoplasms, Antibodies, Monoclonal, Humanized, administration /&/ dosage/adverse effects, Antibodies, Disease-Free Survival, Drug Administration Schedule, methods, Dose-Response Relationship, Breast cancer, Internal medicine, medicine, Humans, Neoplasm Invasiveness, education, Survival analysis, Aged, erbB-2, drug therapy/mortality/pathology, Neoplasm Staging, Chemotherapy, Dose-Response Relationship, Drug, business.industry, Patient Selection, Genes, erbB-2, medicine.disease, Survival Analysis, eye diseases, Neoplasm Recurrence, Genes, pathology, sense organs, Neoplasm Recurrence, Local, business, Adult, Aged, Antibodies, administration /&/ dosage/adverse effects, Antineoplastic Combined Chemotherapy Protocols, administration /&/ dosage/adverse effects, Breast Neoplasms, drug therapy/genetics/mortality/pathology, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Follow-Up Studies, Genes, genetics, Humans, Maximum Tolerated Dose, Middle Aged, Neoplasm Invasiveness, pathology, Neoplasm Recurrence, drug therapy/mortality/pathology, Neoplasm Staging, Patient Selection, Remission Induction, methods, Retreatment, Survival Analysis, Time Factors, Treatment Outcome, Follow-Up Studies

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aba7382055cc3697e1bd7d5369ce2d3Test
    https://doi.org/10.1016/s1470-2045Test(14)70439-5


    أضف إلى المفضلة
  10. 10
    Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l’étude ATHENA France

    المؤلفون: Marc Espié, Alain Lortholary, Katelle Joly, D. Serin, Xavier Pivot, Juana Hernandez, Florence Dalenc, Corinne Veyret, Jean-Yves Pierga, Joseph Gligorov, Anne-Claire Hardy-Bessard, Remy Delva

    المصدر: Bulletin du Cancer. 101:780-788

    مصطلحات موضوعية: Cancer Research, Oncology, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6b635323b1c7bbdc51dc613ed626942bTest
    https://doi.org/10.1684/bdc.2014.2019Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث